67
Participants
Start Date
September 6, 2018
Primary Completion Date
September 23, 2024
Study Completion Date
September 23, 2024
Probio-Tec BG-VCap-6.5
"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10\^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10\^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
Placebo
This placebo is made almost identically to the Probio-Tec but without active microorganisms.
Psychoneuroendocrine Research Program, Dallas
University of Texas Southwestern Medical Center
OTHER